NEW YORK (GenomeWeb News) – Beckman Coulter plans to acquire diagnostics company Biosite for about $1.55 billion in cash, the companies said this weekend.
 
Under the deal, Beckman would pay $85 a share for all of Biosite’s common stock, which closed at $55.38 on the Nasdaq Friday.
 
Beckman, which expects the acquisition will increase its footprint in the immunoassay market, said the deal came from a four-year relationship between the companies based on a test that for coronary syndromes. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.